Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis

Fitzmaurice, 2016, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study, JAMA Oncol, 3, 524, 10.1001/jamaoncol.2016.5688

Owens, 2004, HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues, Clin Breast Cancer, 5, 63, 10.3816/CBC.2004.n.011

Ross, 2009, The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine, Oncologist, 14, 320, 10.1634/theoncologist.2008-0230

Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106

Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152

Wolff, 2007, American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775

Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073

Yaziji, 2004, HER-2 testing in breast cancer using parallel tissue-based methods, JAMA, 291, 1972, 10.1001/jama.291.16.1972

Clinical Practice Guidelines in Oncology (NCCN Guidelines2018

Senkus, 2015, Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v8, 10.1093/annonc/mdv298

von Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N Engl J Med, 377, 122, 10.1056/NEJMoa1703643

Gianni, 2011, Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial, Lancet Oncol, 12, 236, 10.1016/S1470-2045(11)70033-X

Martin, 2017, Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1688, 10.1016/S1470-2045(17)30717-9

Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol Biol Cell, 15, 5268, 10.1091/mbc.E04-07-0591

Bachman, 2004, The PIK3CA gene is mutated with high frequency in human breast cancers, Cancer Biol Ther, 3, 722, 10.4161/cbt.3.8.994

Bedolis, 2004, P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells, Cancer Res, 64, 3981, 10.1158/0008-5472.CAN-03-3900

Diermeier, 2005, Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation, Exp Cell Res, 304, 604, 10.1016/j.yexcr.2004.12.008

Gallardo, 2012, Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas, Br J Cancer, 106, 1367, 10.1038/bjc.2012.85

Lu, 2001, Insulin-like growth factor-i receptor signaling and resistance to trastuzumab (herceptin), J Natl Cancer Inst, 93, 1852, 10.1093/jnci/93.24.1852

Nagy, 2005, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line, Cancer Res, 65, 473, 10.1158/0008-5472.473.65.2

Lumley, 2002, Network meta-analysis for indirect treatment comparisons, Stat Med, 21, 2313, 10.1002/sim.1201

Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparisons, Stat Med, 232, 3105, 10.1002/sim.1875

Hoaglin, 2011, Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2, Value Health, 14, 429, 10.1016/j.jval.2011.01.011

Higgins, 2011, Assessing risk of bias in included studies, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011)

DiasS WeltonN SuttonA AdesA NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials

Higgins, 2012, Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies, Res Synth Methods, 3, 98, 10.1002/jrsm.1044

Dias, 2013, Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials, Med Decis Making, 33, 641, 10.1177/0272989X12455847

Caldwell, 2010, Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency, J Clin Epidemiol, 63, 875, 10.1016/j.jclinepi.2009.08.025

Dias, 2010, Checking consistency in mixed treatment comparison meta-analysis, Stat Med, 29, 932, 10.1002/sim.3767

Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8

Mills, 2013, Demystifying trial networks and network meta-analysis, BMJ, 346, 2914, 10.1136/bmj.f2914

Chan, 2015, Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: primary analysis at 2 years of a phase 3 randomized, placebo-controlled trial (ExteNET), J Clin Oncol, 33, abstr 508, 10.1200/jco.2015.33.15_suppl.508

Gianni, 2016, 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, Lancet Oncol, 17, 791, 10.1016/S1470-2045(16)00163-7

Moja, 2012, Trastuzumab containing regimens for early breast cancer (Review), Cochrane Library, CD006243, 10.1002/14651858.CD006243.pub2

DeMichele, 2015, The neoadjuvant model is still the future for drug development in breast cancer, Clin Cancer Res, 21, 2911, 10.1158/1078-0432.CCR-14-1760

BerryD Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant2014